This increased proportion of patients with gastrinomas having aggressive behavior with higher grades of the primary gastrinoma in sporadic ZES patients correlates with results from prospective NIH clinical studies of patients with either sporadic ZES or ZES with MEN1. This evidence concerns the gene MEN1 and gastrin-producing neuroendocrine tumor.